Union Bancaire Privee UBP SA Invests $282,000 in BioNTech SE (NASDAQ:BNTX)

Union Bancaire Privee UBP SA bought a new stake in BioNTech SE (NASDAQ:BNTX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 2,500 shares of the company’s stock, valued at approximately $282,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Flossbach Von Storch SE grew its holdings in shares of BioNTech by 1.1% during the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company’s stock worth $502,160,000 after purchasing an additional 47,236 shares during the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors acquired a new stake in shares of BioNTech in the 4th quarter valued at about $1,118,000. AlphaCentric Advisors LLC purchased a new position in BioNTech during the 4th quarter worth approximately $168,000. Vontobel Holding Ltd. increased its position in BioNTech by 24.6% during the fourth quarter. Vontobel Holding Ltd. now owns 21,385 shares of the company’s stock worth $2,437,000 after buying an additional 4,227 shares during the period. Finally, Van ECK Associates Corp lifted its stake in BioNTech by 25.1% in the fourth quarter. Van ECK Associates Corp now owns 118,418 shares of the company’s stock valued at $13,493,000 after buying an additional 23,733 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Stock Down 2.5 %

BNTX opened at $116.98 on Tuesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock’s fifty day moving average is $117.32 and its 200-day moving average is $111.29. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a market capitalization of $28.04 billion, a PE ratio of -55.70 and a beta of 0.17.

Wall Street Analysts Forecast Growth

BNTX has been the subject of a number of recent research reports. The Goldman Sachs Group upgraded shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the stock from $90.00 to $137.00 in a research note on Friday, November 8th. Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Evercore ISI raised BioNTech from an “in-line” rating to an “outperform” rating and raised their price target for the stock from $110.00 to $125.00 in a report on Tuesday, November 19th. Canaccord Genuity Group upped their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research note on Wednesday, November 27th. Finally, BMO Capital Markets reaffirmed an “outperform” rating on shares of BioNTech in a research report on Monday, December 2nd. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $142.72.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.